Cetuximab (C225, Erbitux), a chimeric human/murine IgG1 mAb that targets the epidermal growth factor receptor (EGFR/ErbB1), is indicated for the treatment of patients with colorectal and head and neck cancer. Here, EGFR is linked to head and neck cancer.